| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC2901 |
| Trial ID | NCT05201781 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Cilta-cel|JNJ-68284528|LCAR-B38M CAR-T cells |
| Phase | Phase4 |
| Recruitment status | Recruiting |
| Title | Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel |
| Year | 2022 |
| Country | Belgium|China|France|Israel|Japan|Netherlands|Spain|United States |
| Company sponsor | Janssen Research & Development, LLC |
| Other ID(s) | CR109123|2020-005521-84|68284528MMY4002|2023-505530-10-00 |
| Cohort 1 | |||||||||
|
|||||||||